|
Related Party Transactions - Additional Information (Detail) (USD $)
|
3 Months Ended | 9 Months Ended | 12 Months Ended | 1 Months Ended | 2 Months Ended | 1 Months Ended | 12 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 1 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2013
|
Sep. 30, 2012
|
Sep. 30, 2013
|
Sep. 30, 2012
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Jun. 06, 2012
Affiliates of Third Security [Member]
|
Jun. 06, 2011
Affiliates of Third Security [Member]
|
Apr. 08, 2011
Affiliates of Third Security [Member]
|
May 26, 2011
Affiliates of Third Security [Member]
|
May 26, 2011
Affiliates of Third Security [Member]
Series E Redeemable Convertible Preferred Stock [Member]
|
Aug. 31, 2011
Cyntellect Inc [Member]
|
Dec. 31, 2012
Cyntellect Inc [Member]
|
Dec. 31, 2011
Cyntellect Inc [Member]
|
Dec. 31, 2011
Cyntellect Inc [Member]
General and Administrative Expense [Member]
|
Sep. 30, 2013
Chief Executive Officer [Member]
|
Sep. 30, 2012
Chief Executive Officer [Member]
|
Sep. 30, 2013
Chief Executive Officer [Member]
|
Sep. 30, 2012
Chief Executive Officer [Member]
|
Dec. 31, 2012
Chief Executive Officer [Member]
|
Dec. 31, 2011
Chief Executive Officer [Member]
|
Sep. 30, 2013
Affiliates of Preferred Shareholders [Member]
Office
|
Sep. 30, 2012
Affiliates of Preferred Shareholders [Member]
|
Sep. 30, 2013
Affiliates of Preferred Shareholders [Member]
Office
|
Sep. 30, 2012
Affiliates of Preferred Shareholders [Member]
|
Dec. 31, 2012
Affiliates of Preferred Shareholders [Member]
Office
|
Dec. 31, 2011
Affiliates of Preferred Shareholders [Member]
Office
|
Dec. 31, 2012
Shareholder
|
Dec. 31, 2011
Shareholder
|
Jan. 20, 2012
Ziopharm [Member]
|
Feb. 07, 2011
Ziopharm [Member]
|
Jan. 06, 2011
Ziopharm [Member]
|
Sep. 30, 2013
Ziopharm [Member]
|
Dec. 31, 2012
Ziopharm [Member]
|
Sep. 30, 2013
Synthetic Biologics [Member]
|
Dec. 31, 2012
Synthetic Biologics [Member]
|
Sep. 30, 2013
Oragenics [Member]
|
Dec. 31, 2012
Oragenics [Member]
|
Sep. 30, 2013
Oragenics [Member]
Shares Purchased Under Right [Member]
|
Sep. 30, 2013
Soligenix Inc [Member]
|
|
| Related Party Transaction [Line Items] | ||||||||||||||||||||||||||||||||||||||||
| Convertible promissory notes issued | $ 25,000,000 | |||||||||||||||||||||||||||||||||||||||
| Simple interest rate on promissory notes | 12.00% | |||||||||||||||||||||||||||||||||||||||
| Borrowings on convertible promissory notes | 15,000,000 | |||||||||||||||||||||||||||||||||||||||
| Accrued interest on notes | 165,000 | |||||||||||||||||||||||||||||||||||||||
| Shares issued for conversion of convertible promissory notes | 2,888,635 | |||||||||||||||||||||||||||||||||||||||
| Expiration date of a promissory note | Terms of the notes included 12% simple interest annually with principal and interest due on or before June 30, 2011 | |||||||||||||||||||||||||||||||||||||||
| Payment of license fee | 9,000,000 | |||||||||||||||||||||||||||||||||||||||
| Annual exclusivity fee | 1,000,000 | |||||||||||||||||||||||||||||||||||||||
| Milestone payments | 54,000,000 | |||||||||||||||||||||||||||||||||||||||
| Termination period | 90 days | |||||||||||||||||||||||||||||||||||||||
| Stock issued during the period, shares for purchase of assets | 2,386,803 | |||||||||||||||||||||||||||||||||||||||
| Stock issued during the period, value for purchase of assets | 17,000,000 | |||||||||||||||||||||||||||||||||||||||
| Costs associated with asset purchase | 128,000 | |||||||||||||||||||||||||||||||||||||||
| Sublease Income | 91,000 | 0 | 274,000 | 64,000 | 151,000 | 158,000 | 64,000 | 77,000 | ||||||||||||||||||||||||||||||||
| Sublease expired period | May 31, 2012 | |||||||||||||||||||||||||||||||||||||||
| Compensation expense | 388,000 | 388,000 | 1,163,000 | 1,163,000 | 1,550,000 | 210,000 | ||||||||||||||||||||||||||||||||||
| Company leased facility | 2 | 2 | 2 | 2 | ||||||||||||||||||||||||||||||||||||
| Other long term assets | 66,000 | 66,000 | 66,000 | 66,000 | ||||||||||||||||||||||||||||||||||||
| Rent and other facility expenses | 1,272,000 | 1,255,000 | 4,284,000 | 3,739,000 | 5,036,000 | 4,000,000 | 233,000 | 228,000 | 680,000 | 670,000 | 903,000 | 783,000 | ||||||||||||||||||||||||||||
| Related party expense incurred on research and clinical services | 91,000 | 202,000 | ||||||||||||||||||||||||||||||||||||||
| Related party expense amount payable on research and clinical services | 0 | 30,000 | ||||||||||||||||||||||||||||||||||||||
| Purchase commitment | 29,000,000 | 29,000,000 | ||||||||||||||||||||||||||||||||||||||
| Maximum percentage of shares of future securities offerings of collaborative partners to which the entity is entitled to purchase | 19.99% | 19.99% | 30.00% | 30.00% | ||||||||||||||||||||||||||||||||||||
| Additional shares of collaborative partner to which the entity is entitled to purchase on the open market | 10.00% | 10.00% | ||||||||||||||||||||||||||||||||||||||
| Shares of common stock purchased from collaborative partners | 1,923,075 | 1,910,000 | 2,426,235 | 0 | 0 | 1,300,000 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||
| Price per share of common shares | $ 5.20 | $ 5.75 | $ 4.80 | $ 3.00 | ||||||||||||||||||||||||||||||||||||
| Purchase of additional common stock | $ 50,000,000 | |||||||||||||||||||||||||||||||||||||||